Celleron Therapeutics (AgeTech UK) ^Biomed

Cancer treatment, biomarkers. Celleron is building a global oncology company focussed on the clinical development of new and innovative therapies to treat cancer. Celleron’s vision is that the future of cancer therapy lies in the ability to match patients to treatments that are tailored to their tumours – effectively selecting the right drug, at the right dose, for the right patient.

Celleron is developing a novel group of clinical products, supported by predictive companion diagnostics, that act through defined molecular mechanisms to prevent cancer cell growth. The Company’s lead products are in clinical trials, supported by a biomarker platform that allows responsive patients to be identified.

Celleron’s clinical products, CXD101 and CXD201 in Phase II clinical trials, reflect the Company’s deep scientific understanding of epigenetics, cancer biology, and extensive experience clinical trials of novel cancer agents.